文献速递瓣膜外科

生物主动脉瓣置换术后抗血栓策略的系统综述

Antithrombotic Strategies After Bioprosthetic Aortic Valve Replacement: A Systematic Review.
PubMed 文献 · Ann Thorac Surg · 2018-11-17

该系统综述检索至2017年6月,纳入6项临床试验和13项队列研究,比较外科或经导管生物主动脉瓣置换后的抗血栓策略。中等强度证据显示外科bAVR后阿司匹林与华法林在死亡、血栓栓塞和出血方面相似;TAVR后双联抗血小板与单用阿司匹林在死亡、卒中和主要心脏事件方面相似。

要点

  • 外科bAVR后阿司匹林与华法林疗效和出血风险相似。
  • 阿司匹林联合华法林可能小幅降低血栓栓塞和死亡但增加出血。
  • TAVR后单用阿司匹林不劣于双联抗血小板且可能减少出血。

核心结论

  • 外科生物主动脉瓣置换后华法林或阿司匹林治疗结局相似。
  • 阿司匹林联合华法林可能小幅降低血栓栓塞和死亡但增加出血。
  • TAVR后阿司匹林在减少血栓栓塞和死亡方面等效于双联抗血小板治疗,且可能减少出血。

研究设计与样本

  • 系统综述检索Medline、PubMed、Embase、Evidence-Based Medicine Reviews及灰色文献至2017年6月。
  • 纳入直接比较bAVR后不同抗血栓策略的对照临床试验和队列研究。
  • 共审查4554条标题,最终纳入6项临床试验和13项队列研究。

主要发现

  • 外科bAVR后阿司匹林与华法林在死亡率、血栓栓塞事件和出血率方面相似(中等强度证据)。
  • 观察性数据显示外科bAVR后阿司匹林联合华法林较单用阿司匹林死亡和血栓栓塞事件更低,但效应量小且出血风险显著增加。
  • 外科bAVR其他治疗比较证据不足。
  • TAVR患者中双联抗血小板治疗与单用阿司匹林在死亡率、卒中和主要心脏事件方面相似(中等强度证据),单用阿司匹林出血率非显著更低。

临床怎么用

  • 外科bAVR后可根据患者情况选择华法林或阿司匹林。
  • 如需联合阿司匹林与华法林,应权衡小幅血栓栓塞/死亡获益与出血风险增加。
  • TAVR后单用阿司匹林可作为双联抗血小板治疗的替代以减少出血。

局限性

  • 外科bAVR除阿司匹林与华法林比较外其他治疗比较证据不足。
  • 部分结论基于观察性数据,效应量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal antithrombotic regimen after bioprosthetic aortic valve replacement (bAVR) is unclear. We conducted a systematic review of various anticoagulation strategies following surgical or transcatheter bAVR (TAVR). METHODS: We searched Medline, PubMed, Embase, Evidence-Based Medicine Reviews, and gray literature through June 2017 for controlled clinical trials and cohort studies that directly compared different antithrombotic strategies in nonpregnant adults who had undergone bAVR. We assessed risk of bias and graded the strength of the evidence using established methods. RESULTS: Of 4,554 titles reviewed, 6 clinical trials and 13 cohort studies met inclusion criteria. We found moderate-strength evidence that mortality, thromboembolic events, and bleeding rates are similar between aspirin and warfarin after surgical bAVR. Observational data suggest lower mortality and thromboembolic events with aspirin combined with warfarin compared with aspirin alone after surgical bAVR, but the effect size is small and the combination is associated with a substantial increase in bleeding risk. We found insufficient evidence for all other treatment comparisons in surgical bAVR. In TAVR patients, we found moderate-strength evidence that mortality, stroke, and major cardiac events are similar between dual antiplatelet therapy and aspirin alone, though a nonsignificantly lower rate of bleeding occurred with aspirin alone. CONCLUSIONS: Treatment with warfarin or aspirin leads to similar outcomes after surgical bAVR. Combining aspirin with warfarin may lead to a small decrease in thromboembolism and mortality, but is accompanied by increased bleeding. For TAVR patients, aspirin is equivalent to dual antiplatelet therapy for reducing thromboembolism and mortality, with a possible decrease in bleeding.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Papak JN, Chiovaro JC, Noelck N, et al. Antithrombotic Strategies After Bioprosthetic Aortic Valve Replacement: A Systematic Review. Ann Thorac Surg. 2018. PMID: 30458159. doi:10.1016/j.athoracsur.2018.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。